The new methodology makes use of protein engineering incorporating a modified IgM ‘tailpiece’, and has been proven to be efficient in a number of completely different antibodies. This makes it probably engaging as a “plug-and-play” modification device for the most cancers analysis group permitting them to enhance the efficiency of current antibodies or create ‘bio-betters’ from current therapeutics.
Prof Mark Cragg on the University of Southampton mentioned, “Antibody engineering is a fascinating area and allows us to take advantage of the fantastic molecules that nature has evolved to combat infection and improve on them for our therapeutic purposes”.
Researchers at UCB, Dr Shirley Peters and Dr David Humphreys mentioned “This is a great example of grant funding enabling collaborative research which combines the strengths of both academia and industry.
We at UCB could not have so comprehensively studied this invention without the expertise and research community at Southampton. UCB contributed innovative antibody expertise, which founded the concept and will enable it to further develop in the future. We are very pleased to be able to share our joint science with the global community with this paper”.